Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.

NCT03212716 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT03212716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Terminated
Start date
December 23, 2017
Completion date
May 4, 2022
Enrollment
85 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

flu